Tearsheet

Scholar Rock (SRRK)

Market Price (4/11/2026): $49.97 | Market Cap: $6.0 Bil
Sector: Health Care | Industry: Biotechnology

Scholar Rock (SRRK)

Market Price (4/11/2026): $49.97
Market Cap: $6.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Trading close to highs
Dist 52W High is -0.1%, Dist 3Y High is -0.1%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -385 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%

Key risks
SRRK key risks include [1] manufacturing and regulatory delays for its lead asset, Show more.

0	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
1	Trading close to highs Dist 52W High is -0.1%, Dist 3Y High is -0.1%
2	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
3	Very low revenue Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -385 Mil
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
6	Key risks SRRK key risks include [1] manufacturing and regulatory delays for its lead asset, Show more.

Valuation, Metrics & Events

	4/11/26	2025	2024	2023	2022
Share Price CYE	$49.97	$32.15	$17.76	$8.00	$12.89
Market Cap CYE ($ Bil)	6.0	3.6	1.7	0.6	0.5
Total Debt ($ Bil)	0.1	0.1	0.1	0.1	0.1
Total Cash ($ Bil)	0.4	0.4	0.2	0.3	0.2
Enterprise Value ($ Bil)	5.8	3.7	1.8	0.7	0.6
Valuation Ratios
P/S TTM	-	-	-	-	10.2
P/EBIT TTM	-16.0	-13.8	-9.0	-3.8	-4.4
P/E TTM	-15.9	-13.6	-9.3	-3.8	-4.3
P/FCF TTM	-20.0	-15.6	-11.2	-4.8	-3.3
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/11/26	2025	2024
Share Price CYE	$49.97	$32.15	$17.76
Market Cap CYE ($ Bil)	6.0	3.6	1.7
Total Debt ($ Bil)	0.1	0.1	0.1
Total Cash ($ Bil)	0.4	0.4	0.2
Enterprise Value ($ Bil)	5.8	3.7	1.8
Valuation Ratios
P/S TTM	-	-	-
P/EBIT TTM	-16.0	-13.8	-9.0
P/E TTM	-15.9	-13.6	-9.3
P/FCF TTM	-20.0	-15.6	-11.2
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

null

AI Analysis | Feedback

Metric	Value	Date	Source
PDUFA Target Action Date for Apitegromab	September 22, 2025	8142025	Link
Number of Participants in SAPPHIRE Phase 3 Trial (Main Study)	156	10082024	Link
Number of Participants in SAPPHIRE Phase 3 Trial (Ages 13-21 Cohort)	32	10082024	Link
Percentage of SAPPHIRE Trial Patients Enrolled in ONYX Open-Label Expansion Study	98%	10072024	Link
Number of Patients in SAPPHIRE Trial Enrolled in ONYX Open-Label Expansion Study	185	10072024	Link
U.S. Patent Number for Myostatin Inhibitor Combination Therapy	10,946,036	3172021	Link
U.S. Patent Expiry for Myostatin Inhibitor Combination Therapy	June 2037	3172021	Link
U.S. Patent Number for Inhibitors of Myostatin Activation	10,981,981	4262021	Link
U.S. Patent Expiry for Inhibitors of Myostatin Activation	May 2034	4262021	Link

Upcoming
5/13/2026	Earnings Release	Rev: $5.0 Mil (E) EPS: $-0.82 (E)

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Scholar Rock (SRRK) stock has gained about 15% since 12/31/2025 because of the following key factors:

1. Resubmission of Apitegromab Biologics License Application (BLA) to the FDA.

Scholar Rock resubmitted its BLA for apitegromab for spinal muscular atrophy (SMA) to the FDA on March 31, 2026, a significant step forward after receiving a Complete Response Letter in September 2025. This resubmission, which included both the Catalent Indiana LLC facility and a new second U.S.-based fill-finish facility, addressed previous manufacturing concerns and was aligned with FDA guidance. The company anticipates FDA acceptance within 30 days and a potential PDUFA action date in late September 2026, significantly de-risking the regulatory pathway for a key pipeline asset.

2. Positive Analyst Sentiment and Price Target Revisions.

Following the regulatory clarity and BLA resubmission, multiple financial analysts expressed increased optimism for Scholar Rock. JPMorgan raised its price target to $50 from $47, maintaining an Overweight rating, while Piper Sandler increased its target to $58 from $51, also keeping an Overweight rating. Overall, Scholar Rock has received a consensus "Buy" rating from analysts, with an average price target of $54.36, representing a potential upside from its current price.

Show more

Stock Movement Drivers

Fundamental Drivers

The 13.4% change in SRRK stock from 12/31/2025 to 4/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	12312025	4102026	Change
Stock Price ($)	44.05	49.96	13.4%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	114	121	-5.6%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/10/2026

	Return	Correlation
SRRK	13.4%
Market (SPY)	-5.4%	30.9%
Sector (XLV)	-4.8%	34.6%

Fundamental Drivers

The 34.2% change in SRRK stock from 9/30/2025 to 4/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	9302025	4102026	Change
Stock Price ($)	37.24	49.96	34.2%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	113	121	-6.5%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/10/2026

	Return	Correlation
SRRK	34.2%
Market (SPY)	-2.9%	19.6%
Sector (XLV)	6.3%	19.4%

Fundamental Drivers

The 55.4% change in SRRK stock from 3/31/2025 to 4/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312025	4102026	Change
Stock Price ($)	32.15	49.96	55.4%
Change Contribution By:
Total Revenues ($ Mil)	0	0	0.0%
P/S Multiple	∞	∞	0.0%
Shares Outstanding (Mil)	110	121	-9.1%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/10/2026

	Return	Correlation
SRRK	55.4%
Market (SPY)	16.3%	34.4%
Sector (XLV)	2.3%	31.7%

Fundamental Drivers

The 524.5% change in SRRK stock from 3/31/2023 to 4/10/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.

(LTM values as of)	3312023	4102026	Change
Stock Price ($)	8.00	49.96	524.5%
Change Contribution By:
Total Revenues ($ Mil)	33	0
P/S Multiple	19.2	∞	9.2233720368547763E17%
Shares Outstanding (Mil)	80	121	-34.0%
Cumulative Contribution			0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/10/2026

	Return	Correlation
SRRK	524.5%
Market (SPY)	63.3%	4.9%
Sector (XLV)	19.1%	6.4%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
SRRK Return	-49%	-64%	108%	130%	2%	12%	1%
Peers Return	-20%	19%	-1%	-0%	27%	-1%	18%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
SRRK Win Rate	42%	42%	50%	58%	42%	75%
Peers Win Rate	47%	58%	48%	47%	52%	40%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
SRRK Max Drawdown	-50%	-81%	-36%	-62%	-43%	-10%
Peers Max Drawdown	-35%	-21%	-27%	-22%	-39%	-13%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: BIIB, IONS, SRPT, PTCT, REGN. See SRRK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	SRRK	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-93.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1359.7%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-48.9%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	95.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	90 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-75.0%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	299.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	344 days	120 days

Compare to BIIB, IONS, SRPT, PTCT, REGN

In The Past

Scholar Rock's stock fell -93.1% during the 2022 Inflation Shock from a high on 3/15/2021. A -93.1% loss requires a 1359.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Scholar Rock (SRRK)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

AI Analysis | Feedback

1. An early-stage Vertex Pharmaceuticals focused on rare neuromuscular disorders.

2. A developing biotech similar to Biogen, with drugs for neurological diseases, cancer, and fibrosis.

AI Analysis | Feedback

Scholar Rock's major products are experimental drug candidates in various stages of clinical development:

Apitegromab: An inhibitor designed to treat spinal muscular atrophy, having completed Phase 3 clinical trials.
SRK-181: A drug candidate in Phase 1 clinical trials targeting cancers resistant to checkpoint inhibitor therapies.
Novel product candidates: A pipeline of developing therapies aimed at neuromuscular disorders, cancer, and fibrosis.
TGFβ inhibitors: Specific inhibitors of transforming growth factor beta activation being discovered and developed in collaboration with Gilead Sciences for fibrotic diseases.

AI Analysis | Feedback

Scholar Rock (SRRK) is a biopharmaceutical company focused on the discovery and development of medicines. Given its stage of development, with drug candidates primarily in clinical trials, it does not currently have major customers in the traditional sense of selling finished products directly to individuals or end-users.

Instead, its revenue or strategic relationships typically come from collaborations or partnerships with larger pharmaceutical companies that license, co-develop, or acquire its drug candidates. Based on the provided description, the company sells primarily to other companies in this context.

The major customer or strategic partner explicitly mentioned in the background information is:

Gilead Sciences, Inc. (GILD)

AI Analysis | Feedback

null

AI Analysis | Feedback

David Hallal
Chief Executive Officer & Chairman

David Hallal was appointed Chief Executive Officer in April 2025 and has served as Chairman of Scholar Rock's Board of Directors since 2017. Prior to joining Scholar Rock, he spent over a decade as CEO, COO, and CCO of Alexion, where he was responsible for building and leading the company's 50-country operating platform.

Vikas Sinha
Chief Financial Officer

Vikas Sinha was appointed Chief Financial Officer in April 2025. He previously held the position of Chief Financial Officer at Alexion and ElevateBio.

Akshay Vaishnaw M.D., Ph.D.
President, R&D

Akshay Vaishnaw was appointed to the newly created role of President of Research & Development in April 2025. He has been a member of Scholar Rock's Board of Directors since 2019 and previously served as President of Alnylam.

R. Keith Woods
Chief Operating Officer

R. Keith Woods was appointed to the newly created role of Chief Operating Officer in April 2025, with a focus on evolving the organization into a fully integrated global commercial enterprise. He was formerly the Chief Operating Officer of argenx.

Lisa Wyman
Chief Technical and Quality Officer

Lisa Wyman was appointed Chief Technical and Quality Officer in January 2025. She brings over 20 years of leadership and functional experience in technical and quality operations, including executive team responsibilities at Generate:Biomedicines and Acceleron Pharma. Acceleron Pharma was acquired by Merck in 2021.

AI Analysis | Feedback

Key Risks for Scholar Rock (SRRK)

Regulatory approval and commercial success of lead product candidates: Scholar Rock's future revenue and profitability are heavily dependent on the successful regulatory approval and subsequent commercialization of its lead product candidate, Apitegromab, which has completed Phase 3 clinical trials for spinal muscular atrophy. There is no guarantee that Apitegromab will receive regulatory approval or achieve significant market acceptance, which would severely impact the company's business and financial prospects. Similarly, the success of other pipeline candidates, such as SRK-181 (in Phase 1 clinical trials), is critical but also uncertain.
Reliance on a limited number of product candidates: The company's business model is significantly concentrated around the successful development and commercialization of a small number of product candidates, primarily Apitegromab and SRK-181. A setback, failure in clinical trials, or adverse regulatory decision for either of these key programs could have a disproportionately negative impact on Scholar Rock's financial condition and ability to continue operations.

AI Analysis | Feedback

null

AI Analysis | Feedback

Apitegromab (Spinal Muscular Atrophy)

The addressable market for Apitegromab in the treatment of spinal muscular atrophy (SMA) is substantial. In the U.S. market, Apitegromab's revenue is projected to reach an annual total of $433 million by 2037. Globally, the spinal muscular atrophy treatment market size was estimated at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030, growing at a CAGR of 18.0% from 2025 to 2030. Another source projects the global spinal muscular atrophy therapeutics market to rise from USD 6.06 billion in 2026 to USD 13.48 billion by 2031. Scholar Rock plans to launch apitegromab commercially in the US and Europe in 2026 and aims to expand its market reach to 50 countries, targeting 35,000 SMA patients. Analyst estimates indicate peak sales for Apitegromab could reach $1.5 billion.

SRK-181 (Cancers Resistant to Checkpoint Inhibitor Therapies)

SRK-181 targets cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. The global market for checkpoint inhibitor refractory cancer drugs was estimated at USD 42,632.94 million in 2025 and is expected to grow to USD 95,548.35 million by 2032, at a Compound Annual Growth Rate (CAGR) of 12.67% from 2025 to 2032. This market encompasses the expanding patient pool that does not respond to, or progresses after, PD-(L)1 and CTLA-4 checkpoint inhibitor therapy.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Scholar Rock (SRRK)

Over the next 2-3 years, Scholar Rock Holding Corporation's future revenue growth is primarily anticipated to be driven by the following key factors:

U.S. Commercial Launch and Ramp-up of Apitegromab for Spinal Muscular Atrophy (SMA): Scholar Rock is preparing for the U.S. commercial launch of apitegromab in 2026, following a constructive meeting with the FDA and progress in addressing manufacturing facility observations. This therapy aims to be the first muscle-targeted treatment approved for both children and adults with SMA.
European Commercial Launch and Expansion of Apitegromab for SMA: Following the anticipated U.S. launch, a regulatory decision from the European Medicines Agency (EMA) is expected by mid-2026, with a European launch projected for the second half of 2026, starting with Germany. This will open up significant international market access for apitegromab.
Global Market Expansion of Apitegromab: Beyond the initial U.S. and European markets, Scholar Rock plans to establish a 50-country operating platform, targeting a broad patient population of approximately 35,000 SMA patients, with a focus on expansion into regions like Asia-Pacific and Latin America.
Advancement of Apitegromab into Additional Indications and Formulations: The company is actively pursuing the expansion of apitegromab's market potential through further clinical development. This includes the Phase 2 OPAL study evaluating apitegromab in combination with gene therapy for infants and toddlers under two years old with SMA. Additionally, Scholar Rock is exploring the development of a subcutaneous version of apitegromab, which could broaden its administration options and patient reach following the approval of the intravenous formulation.

AI Analysis | Feedback

Share Issuance

Scholar Rock completed an upsized public offering of common stock and pre-funded warrants in October 2024, generating approximately $300 million in gross proceeds to support commercialization, advance clinical programs, and for general corporate purposes.
The company reported $60.4 million from warrant exercises in the fourth quarter of 2025, contributing to its cash balance.

Inbound Investments

Scholar Rock secured a new debt facility of up to $550 million with Blue Owl Capital, with an additional $100 million expected to be drawn by the end of the first quarter of 2026, to support commercial and pipeline initiatives.
The company anticipates monetizing a rare pediatric disease priority review voucher, potentially valued between $150 million and $200 million, upon apitegromab approval.

Capital Expenditures

Annual capital expenditures were $5.25 million in 2021, $1.06 million in 2022, $0.06 million in 2023, $0.10 million in 2024, and $0.60 million in 2025.
Current and planned capital expenditures are focused on commercial readiness and inventory build-out for apitegromab, advancing clinical programs, and developing its technology platform.
The company is investing in a second U.S. fill-finish facility to strengthen supply continuity and support future commercial demand for apitegromab.

Interactive Breakdown

null

null

Better Bets vs. Scholar Rock (SRRK)

null

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	Scholar Rock Earnings Notes	12/26/2025
2	SRRK Dip Buy Analysis	07/10/2025
3	Scholar Rock Total Shareholder Return (TSR): 129.9% in 2024 and 20.3% 3-yr compounded annual returns (above peer average)	03/07/2025
4	Scholar Rock (SRRK) Operating Cash Flow Comparison	02/17/2025
5	Scholar Rock (SRRK) Net Income Comparison	02/16/2025
6	Scholar Rock (SRRK) Operating Income Comparison	02/15/2025
7	Scholar Rock (SRRK) Revenue Comparison	02/13/2025
8	Scholar Rock (SRRK) worth $668 Mil (down $-1.6 Bil), still more valuable than Halliburton	11/07/2024
9	ARTICLES
10	Small Cap Stocks Trading At 52-Week High	04/02/2026
11	Market Movers \| Winners: GES, SRRK, NESR \| Losers: CLDX, LZB, OPEN	08/21/2025

	Title
0	DASHBOARDS
1	Scholar Rock Earnings Notes
2	SRRK Dip Buy Analysis
3	Scholar Rock Total Shareholder Return (TSR): 129.9% in 2024 and 20.3% 3-yr compounded annual returns (above peer average)
4	Scholar Rock (SRRK) Operating Cash Flow Comparison
5	Scholar Rock (SRRK) Net Income Comparison
6	Scholar Rock (SRRK) Operating Income Comparison
7	Scholar Rock (SRRK) Revenue Comparison
8	Scholar Rock (SRRK) worth $668 Mil (down $-1.6 Bil), still more valuable than Halliburton
9	ARTICLES
10	Small Cap Stocks Trading At 52-Week High
11	Market Movers \| Winners: GES, SRRK, NESR \| Losers: CLDX, LZB, OPEN

Trade Ideas

Select ideas related to SRRK.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%
SRRK_11302023_Insider_Buying_45D_2Buy_200K	11302023	SRRK	Scholar Rock	Insider	Insider Buys 45DStrong Insider Buying Companies with multiple insider buys in the last 45 days	-25.4%	216.9%	-43.8%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Mkt Price	49.96	172.97	75.17	21.18	68.69	748.87	71.93
Mkt Cap	6.0	25.4	12.2	2.2	5.6	77.2	9.1
Rev LTM	0	9,891	944	2,198	1,731	14,343	1,964
Op Inc LTM	-385	2,469	-382	-658	857	3,702	237
FCF LTM	-301	1,969	-326	-315	411	3,765	55
FCF 3Y Avg	-216	1,907	-405	-419	-19	3,657	-117
CFO LTM	-300	2,205	-269	-205	711	4,979	253
CFO 3Y Avg	-215	2,209	-359	-304	148	4,664	-34

Growth & Margins

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Rev Chg LTM	-	2.2%	33.8%	15.6%	114.5%	1.0%	15.6%
Rev Chg 3Y Avg	-	-0.9%	19.2%	33.9%	44.9%	5.7%	19.2%
Rev Chg Q	-	-7.1%	-10.3%	-32.7%	-22.7%	2.5%	-10.3%
QoQ Delta Rev Chg LTM	-	-1.7%	-2.4%	-8.9%	-2.7%	0.7%	-2.4%
Op Mgn LTM	-	25.0%	-40.5%	-29.9%	49.5%	25.8%	25.0%
Op Mgn 3Y Avg	-	22.4%	-50.9%	-13.3%	-2.0%	29.0%	-2.0%
QoQ Delta Op Mgn LTM	-	-0.4%	-11.7%	-26.4%	-2.3%	-0.9%	-2.3%
CFO/Rev LTM	-	22.3%	-28.5%	-9.3%	41.1%	34.7%	22.3%
CFO/Rev 3Y Avg	-	22.6%	-46.2%	-20.2%	3.6%	33.6%	3.6%
FCF/Rev LTM	-	19.9%	-34.5%	-14.3%	23.8%	26.3%	19.9%
FCF/Rev 3Y Avg	-	19.5%	-51.9%	-26.7%	-9.8%	26.4%	-9.8%

Valuation

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
Mkt Cap	6.0	25.4	12.2	2.2	5.6	77.2	9.1
P/S	-	2.6	12.9	1.0	3.3	5.4	3.3
P/EBIT	-16.0	13.9	-41.3	-3.3	6.7	14.6	1.7
P/E	-15.9	19.6	-32.0	-3.1	8.3	17.1	2.6
P/CFO	-20.1	11.5	-45.4	-10.8	7.9	15.5	-1.4
Total Yield	-6.3%	5.1%	-3.1%	-32.1%	12.1%	6.3%	1.0%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%
FCF Yield 3Y Avg	-6.1%	7.4%	-5.7%	-7.6%	-4.1%	4.4%	-4.9%
D/E	0.0	0.3	0.2	0.5	0.5	0.0	0.2
Net D/E	-0.0	0.1	-0.1	0.0	0.1	-0.1	0.0

Returns

	SRRK	BIIB	IONS	SRPT	PTCT	REGN	Median
Name	Scholar .	Biogen	Ionis Ph.	Sarepta .	PTC Ther.	Regenero.
1M Rtn	15.7%	-9.2%	0.5%	20.5%	4.6%	-3.3%	2.6%
3M Rtn	18.4%	-7.8%	-6.4%	-11.1%	-11.4%	-5.9%	-7.1%
6M Rtn	26.6%	18.0%	7.4%	-4.2%	3.7%	33.0%	12.7%
12M Rtn	89.9%	52.6%	181.4%	-57.9%	70.5%	37.8%	61.5%
3Y Rtn	522.2%	-39.0%	101.9%	-84.8%	41.6%	-8.0%	16.8%
1M Excs Rtn	15.1%	-9.8%	-0.1%	19.9%	4.0%	-3.9%	1.9%
3M Excs Rtn	21.4%	-5.5%	-6.3%	-7.0%	-9.1%	-4.9%	-5.9%
6M Excs Rtn	28.2%	13.6%	6.5%	-10.3%	5.6%	32.2%	10.1%
12M Excs Rtn	67.4%	14.9%	157.9%	-93.8%	35.9%	-1.6%	25.4%
3Y Excs Rtn	452.1%	-103.4%	46.4%	-151.0%	-21.6%	-74.5%	-48.1%

Comparison Analyses

	Title
0	Scholar Rock Holding vs bluebird bio: Industry Peers; Which Stock Is A Better Bet?
1	Scholar Rock Holding vs Varex Imaging: Similar Market Cap; Which Stock Is A Better Bet?
2	Scholar Rock Holding vs 1-800-FLOWERS.COM: Similar Market Cap; Which Stock Is A Better Bet?
3	Scholar Rock Holding vs Tupperware Brands: Similar Market Cap; Which Stock Is A Better Bet?
4	Scholar Rock Holding vs Adamis Pharmaceuticals: Similar Revenue; Which Stock Is A Better Bet?
5	Scholar Rock Holding vs Alpine Management Systems: Similar Revenue; Which Stock Is A Better Bet?

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	3/3/2026	3/3/2026	2/27/2025	3/19/2024	3/7/2023	3/7/2022	3/9/2021
Key Financials
Total Revenue	0	0	0	0	33	19	15
EBITDA	-374	-369	-238	-168	-131	-127	-85
Operating Income	-385	-385	-252	-171	-134	-130	-87
Net Income	-378	-378	-246	-166	-135	-132	-86
EPS	-3.43	-3.29	-2.47	-1.99	-2.26	-3.59	-2.81
Growth Rates
Total Revenue Growth	-	-	-	-100.0%	76.4%	22.2%	-24.8%
EBITDA Growth	-55.1%	-55.5%	-41.0%	-28.2%	-3.2%	-49.1%	-60.4%
Operating Income Growth	-52.6%	-52.6%	-47.1%	-27.5%	-3.4%	-49.5%	-59.3%
Net Income Growth	-53.5%	-53.5%	-48.6%	-23.3%	-2.1%	-52.4%	-69.6%
Margins
EBITDA Margin	-	-	-	-	-395.8%	-676.5%	-554.4%
Operating Income Margin	-	-	-	-	-404.8%	-690.5%	-564.0%
Net Income Margin	-	-	-	-	-405.2%	-700.5%	-561.5%
Cash & Debt
Total Cash	368	368	437	280	315	253	341
Total Debt	109	109	65	62	69	77	57
Net Debt / (Cash)	-259	-259	-372	-218	-246	-176	-284
Cash Flows
Net Cash from Operations	-300	-300	-201	-145	-133	-127	-60
Free Cash from Operations	-301	-301	-201	-145	-134	-132	-64
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	3/3/2026	11/14/2025	8/6/2025	5/14/2025	2/27/2025	11/12/2024	8/8/2024	5/7/2024	3/19/2024	11/7/2023	8/9/2023	5/9/2023
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-88	-100	-108	-77	-64	-62	-56	-58	-47	-43	-38	-40
Operating Income	-92	-104	-112	-77	-69	-65	-59	-58	-48	-44	-39	-41
Net Income	-91	-102	-110	-75	-66	-64	-59	-57	-46	-42	-38	-39
EPS	-0.88	-0.90	-0.98	-0.67	-0.61	-0.66	-0.60	-0.59	-0.50	-0.53	-0.47	-0.49
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda TTM	-374	-350	-312	-260	-241	-224	-204	-186	-168	-161	-161	-165
Operating Income TTM	-385	-362	-323	-271	-252	-231	-210	-189	-171	-164	-164	-168
Net Income TTM	-378	-353	-316	-264	-246	-226	-204	-183	-166	-159	-160	-166
Growth Rates Quarterly
Total Revenue Growth	-	-	-	-	-	-	-	-	-	-	-	-100.0%
EBITDA Growth	-36.6%	-61.3%	-92.6%	-32.6%	-36.0%	-45.0%	-46.8%	-45.4%	-19.4%	0.4%	9.6%	-543.2%
Operating Income Growth	-32.5%	-59.8%	-88.4%	-32.0%	-44.4%	-48.3%	-52.2%	-44.2%	-18.8%	0.4%	9.4%	-484.3%
Net Income Growth	-36.9%	-58.5%	-88.1%	-31.4%	-44.1%	-52.2%	-54.3%	-44.4%	-17.5%	2.2%	13.8%	-395.3%
Margins Quarterly
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-	-	-	-	-	-	-	-	-	-	-	-
Cash & Debt
Total Cash	368	370	295	364	437	139	190	238	280	219	249	275
Total Debt	109	110	62	63	65	67	68	60	62	63	65	67
Net Debt / (Cash)	-259	-260	-233	-301	-372	-72	-122	-178	-218	-155	-183	-208
Cash Flows Quarterly
FCF from Operations	-75	-69	-77	-79	-50	-52	-49	-50	-37	-32	-33	-43
Cash Flows TTM
FCF from Operations TTM	-300	-274	-258	-230	-201	-189	-169	-152	-145	-137	-131	-133
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-28.6%	-34.7%	-40.5%	-30.6%	-30.2%	-30.0%	-29.6%	-31.7%	-28.1%	-27.2%	-25.7%	-28.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-29.9%	-30.3%	-29.2%	-26.8%	-27.4%	-26.7%	-26.1%	-25.6%	-25.1%	-25.5%	-27.0%	-29.4%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment					15
Total					15

Assets by Segment

$ Mil	2025	2024	2023	2022	2021
Single Segment	475	311	358	304
Total	475	311	358	304

Price Behavior

Price Behavior

Market Price	$49.96
Market Cap ($ Bil)	6.0
First Trading Date	05/24/2018
Distance from 52W High	-0.1%
	50 Days	200 Days
DMA Price	$45.73	$39.30
DMA Trend	up	up
Distance from DMA	9.3%	27.1%
	3M	1YR
Volatility	62.1%	68.7%
Downside Capture	0.24	0.51
Upside Capture	197.16	147.59
Correlation (SPY)	32.4%	24.6%

SRRK Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	1.75	1.91	1.43	1.06	1.28	0.72
Up Beta	-0.95	2.36	3.23	0.89	1.10	1.13
Down Beta	2.62	1.89	1.12	1.87	1.51	0.93
Up Capture	211%	234%	141%	100%	171%	148%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	9	18	29	61	119	368
Down Capture	89%	133%	106%	61%	117%	82%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	13	24	34	65	131	376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	105.2%	69.4%	1.31	-
Sector ETF (XLV)	12.3%	16.8%	0.52	26.1%
Equity (SPY)	31.2%	17.3%	1.47	29.0%
Gold (GLD)	60.1%	27.8%	1.69	-1.2%
Commodities (DBC)	29.8%	16.6%	1.58	10.2%
Real Estate (VNQ)	21.3%	15.2%	1.07	21.5%
Bitcoin (BTCUSD)	-5.7%	43.7%	-0.01	16.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	2.1%	180.5%	0.40	-
Sector ETF (XLV)	6.3%	14.6%	0.25	9.2%
Equity (SPY)	11.1%	17.0%	0.50	9.7%
Gold (GLD)	22.1%	17.8%	1.02	-0.3%
Commodities (DBC)	11.8%	18.8%	0.52	3.9%
Real Estate (VNQ)	3.7%	18.8%	0.10	8.9%
Bitcoin (BTCUSD)	4.0%	56.5%	0.29	6.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with SRRK
SRRK	12.4%	159.3%	0.49	-
Sector ETF (XLV)	9.8%	16.5%	0.48	10.1%
Equity (SPY)	13.8%	17.9%	0.66	10.6%
Gold (GLD)	14.2%	15.9%	0.74	-0.3%
Commodities (DBC)	8.6%	17.6%	0.41	5.2%
Real Estate (VNQ)	5.1%	20.7%	0.22	6.9%
Bitcoin (BTCUSD)	67.4%	66.9%	1.07	4.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	15.7 Mil
Short Interest: % Change Since 3152026	10.1%
Average Daily Volume	2.0 Mil
Days-to-Cover Short Interest	7.9 days
Basic Shares Quantity	120.5 Mil
Short % of Basic Shares	13.1%

Returns Analyses

	Title
0	Scholar Rock Stock Return Comparison
1	[10/3/2021] Scholar Rock Holding (SRRK) Stock Price Forecast: AI Forecasts SRRK Stock Price To Be Around $35.7 In A Month (Up 12%)

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
3/3/2026	1.9%	1.7%	13.1%
11/14/2025	24.4%	26.4%	47.4%
8/6/2025	-6.4%	-12.9%	-12.3%
5/14/2025	-2.7%	0.4%	6.1%
2/27/2025	-2.9%	-2.4%	-9.9%
11/12/2024	-5.3%	-6.3%	49.8%
8/8/2024	-1.0%	11.6%	-2.7%
3/19/2024	14.8%	21.3%	3.8%
...
SUMMARY STATS
# Positive	14	13	11
# Negative	6	7	9
Median Positive	5.2%	11.6%	6.1%
Median Negative	-2.8%	-6.3%	-9.9%
Max Positive	24.4%	32.5%	49.8%
Max Negative	-6.4%	-18.8%	-44.6%

	Forward Returns
3/3/2026	1.9%	1.7%	13.1%
11/14/2025	24.4%	26.4%	47.4%
8/6/2025	-6.4%	-12.9%	-12.3%
5/14/2025	-2.7%	0.4%	6.1%
2/27/2025	-2.9%	-2.4%	-9.9%
11/12/2024	-5.3%	-6.3%	49.8%
8/8/2024	-1.0%	11.6%	-2.7%
3/19/2024	14.8%	21.3%	3.8%
11/7/2023	1.5%	-18.8%	30.9%
8/9/2023	11.3%	9.0%	1.0%
3/7/2023	6.6%	2.3%	-13.2%
11/14/2022	1.1%	0.2%	-0.9%
8/8/2022	6.7%	32.5%	4.9%
5/16/2022	15.0%	-0.6%	-3.3%
3/7/2022	3.7%	-9.5%	-9.9%
11/9/2021	3.8%	24.1%	-8.2%
8/10/2021	3.5%	12.1%	3.3%
3/9/2021	8.3%	15.8%	-44.6%
11/9/2020	-0.5%	2.8%	9.6%
8/7/2020	2.3%	-0.2%	5.0%
SUMMARY STATS
# Positive	14	13	11
# Negative	6	7	9
Median Positive	5.2%	11.6%	6.1%
Median Negative	-2.8%	-6.3%	-9.9%
Max Positive	24.4%	32.5%	49.8%
Max Negative	-6.4%	-18.8%	-44.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	03/03/2026	10-K
09/30/2025	11/14/2025	10-Q
06/30/2025	08/06/2025	10-Q
03/31/2025	05/14/2025	10-Q
12/31/2024	02/27/2025	10-K
09/30/2024	11/12/2024	10-Q
06/30/2024	08/08/2024	10-Q
03/31/2024	05/07/2024	10-Q
12/31/2023	03/19/2024	10-K
09/30/2023	11/07/2023	10-Q
06/30/2023	08/09/2023	10-Q
03/31/2023	05/09/2023	10-Q
12/31/2022	03/07/2023	10-K
09/30/2022	11/14/2022	10-Q
06/30/2022	08/08/2022	10-Q
03/31/2022	05/16/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 3/3/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Debt Facility Drawdown		100.00 Mil
2026 Debt Facility Availability		150.00 Mil

Prior: Q4 2025 Earnings Reported 1/12/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2027 Cash Runway		2,027

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Peng, Katie		Direct	Sell	12182025	44.09	1,006	44,352	1,450,820	Form
2	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	12162025	39.92	29,599	1,181,634	21,159,862	Form
3	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	12052025	45.21	136,462	6,169,788	4,926,535	Form
4	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	37.27	387,414	14,438,544	14,438,544	Form
5	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	38.65	113,025	4,368,808	19,343,703	Form

Collapse to Preview

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Peng, Katie		Direct	Sell	12182025	44.09	1,006	44,352	1,450,820	Form
2	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	12162025	39.92	29,599	1,181,634	21,159,862	Form
3	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	12052025	45.21	136,462	6,169,788	4,926,535	Form
4	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	37.27	387,414	14,438,544	14,438,544	Form
5	Akkaraju, Srinivas		Samsara Opportunity Fund, L.P.	Buy	10072025	38.65	113,025	4,368,808	19,343,703	Form
6	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	9242025	30.67	3,353	102,846	3,342,242	Form
7	Peng, Katie		Direct	Sell	9172025	32.53	1,006	32,726	1,103,240	Form
8	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	9172025	33.52	3,178	106,527	3,764,866	Form
9	Parlavecchio, Caryn	CHRO	Direct	Sell	8192025	31.17	2,178	67,880	4,845,238	Form
10	Flier, Jeffrey S		Trust	Sell	7182025	40.02	11,136			Form
11	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	7102025	34.44	24,066	828,898	3,977,960	Form
12	Flier, Jeffrey S		Direct	Sell	6252025	32.24	20,316	654,904	775,918	Form
13	Flier, Jeffrey S		trust	Sell	6252025	33.21	11,136	369,818	369,818	Form
14	Peng, Katie		Direct	Sell	6172025	31.97	3,031	96,888	1,116,246	Form
15	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	6172025	32.00	3,668	117,381	4,466,147	Form
16	Parlavecchio, Caryn	CHRO	Direct	Sell	6172025	32.00	6,186	197,961	5,044,765	Form
17	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	6172025	32.00	7,442	238,154	7,122,520	Form
18	Flier, Jeffrey S		Direct	Sell	5302025	29.73	6,075	180,584	715,499	Form
19	Burow, Kristina		Direct	Sell	5302025	29.72	5,400	160,511	626,318	Form
20	Gilman, Michael		Direct	Sell	5302025	29.72	3,375	100,304	1,641,004	Form
21	Brudnick, Richard		Direct	Sell	5302025	29.72	6,075	180,531	447,449	Form
22	Reed, Joshua		Direct	Sell	5302025	29.72	5,400	160,463	467,481	Form
23	Vaishnaw, Akshay	President of R&D	Direct	Sell	5302025	29.72	6,750	200,612	18,313,797	Form
24	Sacco, Tracey	Chief Commercial Officer	Direct	Sell	4292025	32.83	5,000	164,131	2,355,277	Form
25	Sacco, Tracey	Chief Commercial Officer	Direct	Sell	3252025	33.08	6,500	215,014	2,373,424	Form
26	Moore, Erin	Interim PFO and PAO	Direct	Sell	3252025	33.12	13,564	449,237	2,735,994	Form
27	Peng, Katie		Direct	Sell	3192025	34.42	1,006	34,627	1,043,592	Form
28	Myles, Edward H	COO & CFO	Direct	Sell	3122025	35.62	142,292	5,068,974	3,966,526	Form
29	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	2202025	36.83	4,135	152,288	4,835,132	Form
30	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	2202025	37.40	68,510	2,562,479	4,154,875	Form
31	Parlavecchio, Caryn	CHRO	Direct	Sell	2202025	36.83	5,296	195,046	5,165,562	Form
32	Myles, Edward H	COO & CFO	Direct	Sell	2202025	36.83	7,809	287,598	5,183,313	Form
33	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	2202025	36.83	5,742	211,472	6,971,546	Form
34	Backstrom, Jay T	CHIEF EXECUTIVE OFFICER	Direct	Sell	2202025	36.83	18,372	676,622	11,490,317	Form
35	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1212026	44.48	8,406	373,880	4,472,589	Form
36	Parlavecchio, Caryn	CHRO	Direct	Sell	1212026	44.48	6,600	293,553	6,621,128	Form
37	Marantz, Jing L	CHIEF MEDICAL OFFICER	Direct	Sell	1212026	44.48	5,798	257,882	4,255,938	Form
38	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	1212026	44.48	8,016	356,533	9,542,824	Form
39	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1162026	45.20	13,112	592,611	4,924,748	Form
40	Sinha, Vikas	Chief Financial Officer	Direct	Sell	1152026	42.70	16,755	715,438	24,904,562	Form
41	Woods, Keith	Chief Operating Officer	Direct	Sell	1152026	42.70	16,746	715,054	24,904,946	Form
42	Vaishnaw, Akshay	President of R&D	Direct	Sell	1152026	42.70	20,438	872,703	25,439,251	Form
43	Hallal, David	Chief Executive Officer	Direct	Sell	1152026	42.70	57,450	2,453,115	65,828,242	Form
44	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	1232026	46.71	14,898	695,938	4,001,477	Form
45	Parlavecchio, Caryn	CHRO	Direct	Sell	2192026	46.53	9,035	420,382	7,867,314	Form
46	Qatanani, Mo	CHIEF SCIENTIFIC OFFICER	Direct	Sell	2192026	46.53	7,989	371,714	4,975,214	Form
47	Marantz, Jing L	CHIEF MEDICAL OFFICER	Direct	Sell	2192026	46.53	4,157	193,418	5,863,112	Form
48	Ho, Junlin	GENERAL COUNSEL	Direct	Sell	2192026	46.53	9,580	445,740	11,238,654	Form

SRRK Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing SRRK?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What SRRK Makes & Who Pays

TTM figures based on

SRRK Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Scholar Rock (SRRK)

Market Price (4/11/2026): $49.97 | Market Cap: $6.0 BilSector: Health Care | Industry: Biotechnology

Scholar Rock (SRRK)

Market Price (4/11/2026): $49.97Market Cap: $6.0 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Scholar Rock (SRRK)

Key Risks for Scholar Rock (SRRK)

Expected Drivers of Future Revenue Growth for Scholar Rock (SRRK)

Share Issuance

Inbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Scholar Rock (SRRK)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

FDA Approved Drugs Data

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Recent Forward Guidance [BETA]

Insider Activity

SRRK Trade Sentinel

null

CONVICTION RATIONALE

STOCK ARCHETYPE

INVESTMENT THESIS

PRIMARY RISK

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Position Sizing

Market Price (4/11/2026): $49.97 | Market Cap: $6.0 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (4/11/2026): $49.97
Market Cap: $6.0 Bil
Sector: Health Care
Industry: Biotechnology